Current approaches to the external therapy of psoriasis



Cite item

Full Text

Abstract

Topical glucocorticosteroids rank first among drugs for the external therapy of psoriasis. When selecting a drug, it is necessary to take into account the disease sensitivity to different classes of topical steroids. Dermovate (clobetasol propionate) is the most efficient drug for the external therapy of moderate to severe psoriasis. When this drug was used as a part of the complex treatment of psoriasis, regression of eruptions was observed within three weeks in 97.4% of patients, and in 91.5% of patients if the process was localized in the area of palms and soles. Major indications for its use are torpidity with regard to the previous therapy, localization in the field of palms and soles, and substantial reduction in the life quality.

Full Text

Современные подходы к наружной терапии псориаза
×

About the authors

A N KHLEBNIKOVA

Email: Alb9696@yandex.ru

References

  1. Krueger G., Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004; 140: 218—225.
  2. Glowacka E., Lewkowicz P., Rotsztein H. et al. IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils—fibroblasts interaction in psoriasis. ADV Med Sci 2010; 55: 254—260.
  3. Ghadially R., Reed J.T., Elias P.M. Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol 1996; 107: 558—564.
  4. Lew b.l., Cho Y., Kim J. et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-αlpha, and JNK. J Korean Med Sci 2006; 21: 95—99.
  5. Молочков В.А., Бадокин В.В., Альбанова В.И. и др. Псориаз и псориатический артрит. Товарищество научных изданий КМК, М., 2007; 300 с.
  6. Olsen E.A., Cornell R.C. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15: 246—255.
  7. Hehir M., duVivier A., Eilon L. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983; 8: 143—151.
  8. Portner M., Mollmann H., Rohdewald P. Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters. Pharm Res 1988; 5: 623—627.
  9. Jacobson C., Cornell R.C., Savin R.C. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis 1986; 37: 213—220.
  10. Pearce D.J., Stealey K.H., Balkrishnan R. et al. Psoriasis treatment in the United States at the end of the20th century. Int J Dermatol 2006; 45: 370—374.
  11. Bleeker J. Double-blind comparison between two new topical corticosteroids, halcinonide 0.1% and clobetasol propionate cream 0.05%. Curr Med Res Opin 1975; 3: 225—228.
  12. Corbett M.F. The response of psoriasis to betamethasone valerate and clobetasol propionate: a 6-month controlled study. Br J Dermatol 1976; 94(suppl 12): 89—93.
  13. Jegasothy B., Jacobson C., Levine N. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol 1985; 24: 461—465.
  14. Gip L., Hamfelt A. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses. Cutis 1984, 33: 215—223.
  15. Gould P.W., Wilson L. Psoriasis treated with clobetasol propionate and photochemotherapy. Br J Dermatol 1978; 98: 133—136.
  16. Hradil E., Lindstrom C., Moller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol 1978; 58: 375—377.
  17. Svartholm H., Larsson L., Frederiksen B. Intermittent topical treatment of psoriasis with clobetasol propionate (“Dermovate”). Curr Med Res Opin 1982; 8: 154—157.
  18. Staughton R.C., August P.J. Cushing’s syndrome and pituitary-αdrenal suppression due to clobetasol propionate. Br Med J 1975; 24: 419—421.
  19. Lawlor F., Ramabala K. Iatrogenic Cushing's syndrome — a cautionary tale. Clin Exp Dermatol 1984; 9: 286—289.
  20. Gen R., Akbay E., Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci 2007; 333: 173—174.
  21. Poulin Y., Papp K., Bissonnette R. et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatol Treat 2010; 21: 185—192.
  22. Feldman S.R. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis 2007; 80(5 Suppl): 20—28.
  23. Gottlieb A.B., Ford R.O., Spellman M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185—192.
  24. Reid D.C., Kimball A.B. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005; 6: 1735—1740.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 KHLEBNIKOVA A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies